CD8A and neoplasm: In drug sensitivity analysis, the BET inhibitor JQ1, which showed heightened efficacy in the high-risk subgroup, has been reported to influence tumor progression by enhancing the cytotoxicity of CD8+ T cells and reducing regulatory T cell (Treg) infiltration in the tumor microenvironment (21).